Scatena R. (Ed.) Advances in Cancer Biomarkers: From biochemistry to clinic for a critical revision

Dordrecht: Springer Netherlands, 2015. — 372 p. — (Advances in Experimental Medicine and Biology 867). — ISBN: 978-94-017-7214-3, 978-94-017-7215-0.Contributes to a careful knowledge of the biochemistry, pathophysiology and clinics of cancer biomarkers
Promotes an optimal clinical use of cancer biomarkers
Facilitates the understanding of the real diagnostic index of old and new cancer biomarkers
Fosters a rational clinical approach to the diagnosis and prognosis of cancerAt present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirely know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and “polluted” knowledge may have dramatic consequences for patient. The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology.
This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation.Cancer Biomarkers: A Status Quo
Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives
Use of Biomarkers in Screening for Cancer
The Role of Metabolomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools
The Role of Epigenomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools
Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development
Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects
The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects
Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects
Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer
The Role of Human Chorionic Gonadotropin as Tumor Marker: Biochemical and Clinical Aspects
Biomarkers for Hepatocellular Carcinoma (HCC): An Update
Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer
The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects
CA 19-9: Biochemical and Clinical Aspects
Non Coding RNA Molecules as Potential Biomarkers in Breast Cancer
Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects
Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer
A Critical Approach to Clinical Biochemistry of Chromogranin A
The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer
The Role of CTCs as Tumor Biomarkers